Start-Up Quarterly Statistics, Q4 2010
This article was originally published in Start Up
Biopharma, medical device and in vitro diagnostics start-ups brought in a total of $548 million in Q4 2010, a 30% drop from the previous quarter and a 24% decrease from Q4 2009. Six start-up acquisitions were completed - five in the biopharmaceutical industry and one diagnostic transaction. In the fourth quarter there were 27 start-up biopharma alliances covering a wide range of therapeutic categories, and fourteen of them involved large molecules.
You may also be interested in...
Investments for start-ups seeking their first infusion of venture capital continues to be scarce as venture firms seek later-stage opportunities and liquidity to improve their own chances of raising new funds.
Thanks to a November restructuring that refocused the company around its historic strength in neurology and the hiring of two critical executives, Biogen believes it can grow beyond its warhorses Avonex and Tysabri
Ablexis LLC's October 2010 consortium-based alliance with Pfizer Inc. and four other undisclosed "Top 15" drugmakers represents an important new variation in platform-technology deal-making.